Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» HAE
HAE
KalVista files first oral on-demand HAE drug with FDA
Pharmaphorum
Tue, 06/18/24 - 11:23 am
KalVista
HAE
sebetralstat
FDA
Ionis reveals an oasis for HAE patients as RNA med reduces attacks in phase 3
Fierce Biotech
Fri, 05/31/24 - 11:00 am
Ionis Pharmaceuticals
HAE
clinical trials
donidalorsen
Intellia’s CRISPR drug could offer one-shot HAE treatment
Pharmaphorum
Thu, 02/1/24 - 11:26 am
Intellia Therapeutics
HAE
clinical trials
CRISPR
gene editing
NTLA-2002
Ionis says rare disease drug succeeds in late-stage HAE study
BioPharma Dive
Mon, 01/22/24 - 11:10 am
Ionis Pharmaceuticals
HAE
clinical trials
donidalorsen
Pharvaris' oral hereditary angioedema med slashes attacks in turnaround post-FDA hold
Fierce Biotech
Wed, 12/6/23 - 10:34 am
Pharvaris
HAE
clinical trials
deucrictibant
CRISPR on the Cusp: The Promise and the Pain Points
BioSpace
Mon, 07/10/23 - 09:27 pm
Intellia Therapeutics
HAE
NTLA-2002
CRISPR
Patients attack-free a year after receiving Intellia's hereditary angioedema CRISPR med
Fierce Biotech
Sun, 06/11/23 - 11:07 pm
Intellia Therapeutics
HAE
hereditary angiodema
CRISPR
NTLA-2002
CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing
Drugs.com
Wed, 03/1/23 - 10:07 am
CSL
clinical trials
garadacimab
HAE
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
Yahoo Finance
Sun, 11/13/22 - 06:59 pm
Ionis Pharmaceuticals
clinical trials
donidalorsen
hereditary angiodema
HAE
Pharvaris studies of rare disease drug put on hold by FDA
BioPharma Dive
Mon, 08/22/22 - 08:12 pm
Pharvaris
FDA
hereditary angiodema
HAE
PHA121
CSL reports Phase III data for garadacimab to treat hereditary angioedema
Clinical Trials Arena
Thu, 08/18/22 - 12:30 pm
CSL
clinical trials
garadacimab
HAE
hereditary angiodema
Intellia doses first patient as hereditary angioedema gene editing therapy lands in clinic
Fierce Biotech
Mon, 12/13/21 - 11:46 pm
Intellia Therapeutics
HAE
clinical trials
NTLA-2002
Takeda, CSL hereditary angioedema meds need steep discounts following real-world evidence review, ICER says
Fierce Pharma
Wed, 08/25/21 - 09:32 pm
Takeda
CSL
hereditary angiodema
HAE
RWE
Takhzyro
Cinryze
Haegarda
BioCryst's persistence for patient insights leads to a bigger market for HAE drug Orladeyo
Fierce Pharma
Tue, 05/25/21 - 11:53 pm
Biocryst
HAE
patients
Regulatory progress for two biotechs stalls as FDA requests more information
MedCity News
Wed, 04/21/21 - 10:30 am
KalVista
Y-mAbs Therapeutics
FDA
KVD824
HAE
FDA slaps a hold on KalVista's PhII study of an HAE drug, raising a red flag on preclinical results
Endpoints
Tue, 04/20/21 - 11:14 am
KalVista
HAE
FDA
clinical trials
KVD824
Mid-stage angioedema hit sends Kalvista though the roof
EP Vantage
Tue, 02/9/21 - 11:23 am
KalVista
HAE
hereditary angiodema
KVD900
BioCryst takes on Takeda, CSL with FDA approval for Orladeyo, the first pill to prevent HAE attacks
Fierce Pharma
Sat, 12/5/20 - 11:26 pm
Biocryst
Orladeyo
HAE
FDA
Takeda
CSL Behring
Pharvaris lands another $80M as it looks to tackle Takeda and CSL with an oral approach for HAE
Endpoints
Wed, 11/18/20 - 11:07 pm
Pharvaris
HAE
Takeda
CSL
BioCryst Plans to Raise $100 Million
Motley Fool
Wed, 05/27/20 - 11:51 pm
drug launches
Biocryst
HAE
berotralstat
Pages
1
2
3
next ›
last »